Literature DB >> 14709621

Metabolism of apigenin by rat liver phase I and phase ii enzymes and by isolated perfused rat liver.

Angéline Gradolatto1, Marie-Chantal Canivenc-Lavier, Jean-Philippe Basly, Marie-Hélène Siess, Caroline Teyssier.   

Abstract

The metabolism of apigenin, a low estrogenic flavonoid phytochemical, was investigated in rat using liver models both in vitro (subcellular fractions) and ex vivo (isolated perfused liver). In vitro, phase I metabolism led to the formation of three monohydroxylated derivatives: luteolin which was the major metabolite (K(m) = 22.5 +/- 1.5 microM; V(max) = 5.605 +/- 0.090 nmol/min/mg protein, means +/- S.E.M.), scutellarein, and iso-scutellarein. These oxidative pathways were mediated by cytochrome P450 monooxygenases (P450s). The use of P450 inhibitors and inducers showed that CYP1A1, CYP2B, and CYP2E1 are involved. In vitro studies of phase II metabolism indicated that apigenin underwent conjugation giving three monoglucuronoconjugates and one monosulfoconjugate. Luteolin led to the formation of four monoglucuronoconjugates, two sulfoconjugates, and one methylconjugate identified as diosmetin. Ex vivo during the apigenin perfusion of an isolated rat liver, none of the phase I metabolites could be recovered. In contrast, two monoglucuronoconjugates and one of the sulfoconjugates of apigenin already identified in vitro were recovered. Moreover, two new derivatives were isolated and identified as a diglucuronoconjugate and a glucuronosulfoconjugate. This work provides new data about the metabolism of apigenin and shows the interest value of using various experimental models in metabolic studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709621     DOI: 10.1124/dmd.32.1.58

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Bioavailability challenges associated with development of anti-cancer phenolics.

Authors:  Song Gao; Ming Hu
Journal:  Mini Rev Med Chem       Date:  2010-06       Impact factor: 3.862

2.  The Flavonoid Apigenin Is a Progesterone Receptor Modulator with In Vivo Activity in the Uterus.

Authors:  Matthew Dean; Julia Austin; Ren Jinhong; Michael E Johnson; Daniel D Lantvit; Joanna E Burdette
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

Review 3.  Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity.

Authors:  Gregory L Hostetler; Robin A Ralston; Steven J Schwartz
Journal:  Adv Nutr       Date:  2017-05-15       Impact factor: 8.701

4.  Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways.

Authors:  Wen Jiang; Ming Hu
Journal:  RSC Adv       Date:  2012-09-21       Impact factor: 3.361

5.  Proteomic study of granulocytic differentiation induced by apigenin 7-glucoside in human promyelocytic leukemia HL-60 cells.

Authors:  Eri Nakazaki; Soninkhishig Tsolmon; Junkyu Han; Hiroko Isoda
Journal:  Eur J Nutr       Date:  2011-11-24       Impact factor: 5.614

6.  Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry.

Authors:  Yu-Qi He; Li Yang; Yong Liu; Jiang-Wei Zhang; Jun Tang; Juan Su; Yuan-Yuan Li; Yan-Liu Lu; Chang-Hong Wang; Ling Yang; Zheng-Tao Wang
Journal:  Acta Pharmacol Sin       Date:  2009-09-21       Impact factor: 6.150

7.  Protective effects of kaempferol on isoniazid- and rifampicin-induced hepatotoxicity.

Authors:  Tung-Yuan Shih; Ton-Ho Young; Herng-Sheng Lee; Chung-Bao Hsieh; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

8.  Design, synthesis, and characterization of novel apigenin analogues that suppress pancreatic stellate cell proliferation in vitro and associated pancreatic fibrosis in vivo.

Authors:  Haijun Chen; Amy A Mrazek; Xiaofu Wang; Chunyong Ding; Ye Ding; Laura J Porro; Huiling Liu; Celia Chao; Mark R Hellmich; Jia Zhou
Journal:  Bioorg Med Chem       Date:  2014-05-02       Impact factor: 3.641

Review 9.  Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?

Authors:  Eva F DeRango-Adem; Jonathan Blay
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

10.  Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression.

Authors:  Kavon Rezai-Zadeh; Jared Ehrhart; Yun Bai; Paul R Sanberg; Paula Bickford; Jun Tan; R Douglas Shytle
Journal:  J Neuroinflammation       Date:  2008-09-25       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.